Here are the 10-Q quarterly reports from Adaptin Bio Inc (APTN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow APTN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APTN filings page.
Adaptin Bio, Inc. reports continued operating losses and tight liquidity for the quarter ended June 30, 2026. The company, which is developing its BRiTE platform and lead bispecific T‑cell engager APTN‑101 for brain cancers, recorded a three‑month net loss of $1.21 million and a six‑month net loss of $2.35 million, with an accumulated deficit of $11.64 million.
Operating expenses for the quarter fell 21% year over year to $1.20 million, driven largely by a 59% reduction in research and development as several preclinical programs and a tox study wound down, partially offset by higher stock‑based compensation and personnel costs. Net cash used in operating activities for the first half of 2026 declined 68% to $1.05 million.
Adaptin ended June 30, 2026 with $670,488 in cash and cash equivalents and a stockholders’ deficit of $1.67 million. Management states that these levels, together with planned development spending and a working capital deficit, create substantial doubt about the company’s ability to continue as a going concern without additional financing. The company raised $912,000 in follow‑on private placements and $669,106 net from warrant exercises during the first half, and reports outstanding equity‑classified warrants for 2,461,381 shares. Internal control weaknesses around non‑routine transactions, R&D accruals, and income tax accounting remain unresolved.
Adaptin Bio, Inc. reported a Q1 2026 net loss of $1,146,096, wider than the prior-year loss of $603,084, as it increased investment in R&D and public-company overhead.
The company ended March 31, 2026 with cash and equivalents of $301,309 and an accumulated deficit of $10,437,897. Management disclosed that these conditions raise substantial doubt about its ability to continue as a going concern and expects to rely on additional equity or debt financings. During the quarter, Adaptin raised gross proceeds of $652,000 through its Follow-on Offering, issued 130,400 new shares, and continued advancing its APTN-101 brain cancer program while operating with a working capital deficit.